Vortioxetine filed in the US and EU – Revenue from New Products doubled

Third quarter report 2012
Vortioxetine filed in the US and EU – Revenue from New Products doubled

H. Lundbeck A/S (Lundbeck) reports revenue of DKK 3,563 million for the third quarter of 2012, excluding Lexapro® in the US, an increase of 2% compared to the same period last year. EBITDA and EBIT were DKK 846 million and DKK 661 million respectively, corresponding to an EBITDA margin of 23.4% and an EBIT margin of 18.2%. Profits were affected by the increase in launch costs associated with Lundbeck's newer products, as well as the loss of revenue from Lexapro due to generic competition.
- Lundbeck's novel multimodal antidepressant, vortioxetine, filed in Europe, Canada and the US - a treatment that may benefit patients with depression who are seeking additional therapeutic options
- New Products* increased 100% and constituted 17% of revenue for the third quarter
- OnfiTM revenue in the US is on track to meet expectations and generated revenue of DKK 174 million for the first nine months of 2012
- Escitalopram in Japan now holds a market share of 6.1% and for the first nine months generated a royalty of DKK 133 million
- Third quarter revenue in the US, excluding Lexapro, increased 44%
- Treanda® launched in Canada, and Azilect® launched in Thailand, Hong Kong and Australia
- Lundbeck is on track to meet financial expectations for 2012

Click here to read the full report >> (PDF)

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.